Docs advocate for novel biosimilar names


Ever since the FDA drafted a set of rules for biosimilars in 2012, a debate has been raging over whether those drugs should carry the same generic names as the products they emulate. Now, some doctors are weighing in on the issue, urging the FDA to require biosimilars to have different names than branded biotech drugs.

Continue reading

From John: Fall Congressional Outlook


It is August and that means that congress is on vacation. Vacation from doing what?  I don’t know. (note I do believe that our elected officials are hard working) But when they return after Labor Day, there are a number of issues that they are going to have to deal with before taking a longer recess for their elections.

Continue reading

Studies Show Economic Benefit to Specialty Pharma Drugs like Sovaldi #reducethecopay


On July 16th I wrote a piece about hi-copay specialty tiers, and how insurance companies are using them to restrict access to specialty pharma. In the hi-copay specialty tier, instead of pay a flat fee for the medications, patients must instead pay for a percentage of the drug cost, anywhere from 20%-50%.

Continue reading

Politicians Shouldn’t Question Drug Costs But Rather Their Value. Lessons From Soliris And Sovaldi.

Originally posted on Forbes


Hepatitis C Medicines Impact on Medicare Part D

Originally posted on Pharmalot


In the latest salvo fired over the cost of hepatitis C treatments, a new report projects that the cost of these drugs – including the Sovaldi medication sold byGilead Sciences GILD +0.74% – will increase 2015 federal spending by Medicare Part D between $2.9 billion to $5.8 billion.

Continue reading